Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Individualized Duration of Peg-interferon/Ribavirin Treatment of Hepatitis C (TTG1)
This study has been completed.
Study NCT00910975 Information provided by Göteborg University
First Received on May 28, 2009. Last Updated on September 3, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Chronic Hepatitis C, Genotype 1
Additional conditions recognized in this trial
Hepatitis
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
Hepatitis, Chronic
More general conditions related to this trial
Digestive System Diseases
Enterovirus Infections
Flaviviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Interventions listed in this trial
Peg-interferon-alfa2a (Pegasys)
Ribavirin (Copegus)
Additional drug interventions recognized in this trial
Interferon Alfa-2a
Interferon-alpha
Interferons
Peginterferon alfa-2a
Ribavirin
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Infective Agents
Antimetabolites
Antineoplastic Agents
Antiviral Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Göteborg University
Sahlgrenska University Hospital, Sweden
Sodra Alvsborgs Hospital
Skaraborg Hospital
Uddevalla Hospital
Skane University Hospital
Lund University Hospital
Karolinska University Hospital
Back to top of Main Content
